Skip to main content
PLOS ONE logoLink to PLOS ONE
. 2021 Mar 25;16(3):e0247378. doi: 10.1371/journal.pone.0247378

Stool metabolome-microbiota evaluation among children and adolescents with obesity, overweight, and normal-weight using 1H NMR and 16S rRNA gene profiling

José Diógenes Jaimes 1,#, Andrea Slavíčková 1,, Jakub Hurych 2,, Ondřej Cinek 2,3,, Ben Nichols 4, Lucie Vodolánová 2, Karel Černý 5, Jaroslav Havlík 1,*,#
Editor: Suzanne L Ishaq6
PMCID: PMC7993802  PMID: 33765008

Abstract

Characterization of metabolites and microbiota composition from human stool provides powerful insight into the molecular phenotypic difference between subjects with normal weight and those with overweight/obesity. The aim of this study was to identify potential metabolic and bacterial signatures from stool that distinguish the overweight/obesity state in children/adolescents. Using 1H NMR spectral analysis and 16S rRNA gene profiling, the fecal metabolic profile and bacterial composition from 52 children aged 7 to 16 was evaluated. The children were classified into three groups (16 with normal-weight, 17 with overweight, 19 with obesity). The metabolomic analysis identified four metabolites that were significantly different (p < 0.05) among the study groups based on one-way ANOVA testing: arabinose, butyrate, galactose, and trimethylamine. Significantly different (p < 0.01) genus-level taxa based on edgeR differential abundance tests were genus Escherichia and Tyzzerella subgroup 3. No significant difference in alpha-diversity was detected among the three study groups, and no significant correlations were found between the significant taxa and metabolites. The findings support the hypothesis of increased energy harvest in obesity by human gut bacteria through the growing observation of increased fecal butyrate in children with overweight/obesity, as well as an increase of certain monosaccharides in the stool. Also supported is the increase of trimethylamine as an indicator of an unhealthy state.

Introduction

The proportion of children and adolescents aged 5 to 19 considered overweight has risen globally from approximately 1 in 10 in the mid-1970s to about to about 1 in 5 in 2016 [1]. There is strong evidence of a close relationship between childhood overweight/obesity and multiple comorbidities which, collectively, reduce life expectancy and increase mortality. This has become an emerging public health problem that has attracted the wide attention of researchers [24]. Identifying potential biomarkers in pediatric populations via metabolomics and 16S rDNA profiling can provide an opportunity not only to identify these conditions, but to find potential prevention and treatment approaches.

Despite inter-individual differences, approaches using 16S rRNA gene amplicon sequencing (16S rDNA profiling) of fecal samples have shown differing gut bacterial composition between children with obesity and those without [5]. For example, at the phylum level, a high Firmicutes/ Bacteroidetes ratio (decrease in Bacteroidetes, increase in Firmicutes) has been associated with obesity [68], and even specific strains such as F. prausnitzii have been positively correlated with BMI z-score [8]. Nevertheless, there is inconsistency in these observations and knowledge about the specific gut microbiota members relevant to the characterization of overweight/obesity remain elusive [6, 9, 10]. Furthermore, microbiome studies have thus far tended to focus on adult populations; consequently, compositional and functional differences between children and adult cohorts have not been reported [11].

Although powerful, 16S rDNA profiling falls short in telling us about the functional activities of the gut microbiota [12]. Another omics approach that helps fill this void is metabolomics. Fecal metabolomics in particular reports on the interaction between host, diet, and the microbiota, thus complementing 16S profiling by providing a functional readout of the microbiota [12, 13] and thus providing a characterization of the molecular phenotype [1416]. Metabolomic studies have observed certain metabolic patterns and signatures as potential biomarkers of obesity. For example, studies using various biofluids have observed that an increased level of branched-chain amino acids (valine, leucine, isoleucine) and of aromatic amino acids (tyrosine, tryptophan, phenylalanine, methionine) appear to characterize the presence, and, in some cases, the propensity for obesity [2, 17, 18]. Nevertheless, further research is necessary to test whether proposed biomarker metabolites can be considered an established and specific metabolic signature [17]. Furthermore, it is important to differentiate metabolomic profile differences between children and adults; for example, one striking observed difference in childhood obesity in contrast to adult obesity is that impairment of fasting glucose levels is usually absent and, if present, it is a delayed finding [2]. A recent example integrating 16S rDNA profiling and metabolomics observed that 67.7% of the fecal metabolome variance was explained by the gut microbiota composition [12] and it has been widely observed that changes in metabolite levels are often associated with the microbiota [2, 5, 17, 19]. This high degree of association between the microbiota and the fecal metabolome makes integration of these two omics technologies a powerful investigative strategy.

This study integrates these two omics approaches. Using stool samples as the analytical matrix and an untargeted approach, we aimed to uncover potential metabolomic and gut bacterial biomarkers of childhood overweight/obesity in a group of 52 Czech children/adolescents aged 7 to 16 years. The analytical platforms used were 1H NMR to evaluate the metabolomic profile and 16S rRNA gene sequencing to assess the gut bacteria composition. The significant results from each were then correlated to better define metabolome-gut bacteria relations.

Methods

Study participants

This is an observational study to characterize differences in the stool metabolome and bacteriome among 52 Czech youth (28 females, 24 males) aged 7 to 16 years classified into three comparison groups (normal-weight, overweight, and obese). The study was performed according to the Declaration of Helsinki and was approved by the Ethical Committee of the University Hospital Královské Vinohrady, reference number LEK-VP / 01/0/2018. All participants and their parents agreed to participate by signing appropriate written informed consents. These written informed consents were provided by the parents for the participation of their children in the study. The inpatient study took place during an eight-week period between late July to late September 2018.

Participant recruitment was carried out by the Olivova Children’s Medical Institution (Olivova Dětská Léčebna) in Říčany, Czech Republic, from their then-present patient population. Recruitment criteria consisted of youth who were between 6 and 18 years of age, had no antibiotic intake for the past three months, were not currently taking any medication, and were physically healthy to take part in a physical activity program led by physiotherapists focused on aerobic activity, strengthening, and stretching twice a day on weekdays. The subjects considered overweight and obese were under treatment/rehabilitation of their overweight/obesity condition through diet and physical activity. The control group (normal weight) were youth with either a respiratory disease (chronic upper and lower respiratory cataracts, bronchial asthma, allergies) or with an orthopedic diagnosis (scoliosis, poor posture, patients after surgery). To minimize the potential of these conditions being confounding, those with a respiratory disease had to be in remission (not in an acute stage) whose only treatment was climatotherapy and respiratory physiotherapy. Those with an orthopedic diagnosis were also only receiving physiotherapy. Out of 121 identified youth who met these conditions, 52 of them ultimately agreed (along with their parents) and/or completed the entire study process. Once in the study, all participants were interned at Olivova for an eight-week period during which they underwent a similar physical activity regime and all received a similar diet (same ingredients, same dishes). The portion size for each participant was based on their age, gender, and weight. Those classified as overweight/obese received 30% less kilocalories than recommended for their age and gender, thus placing them on a caloric restriction. It is important to note that the diet was planned by a clinical dietitian, the meals and snacks were prepared by the Olivova cafeteria kitchen, and the composition of each meal (kilocalories, macronutrient composition) was known as determined by the disaggregated ingredients of each meal through the use of the Nutriservis Profi software (https://nutriservis.cz), a database of approximately 5000 ingredients, including over 900 Czech ones. There were three main meals provided (breakfast, lunch, dinner) plus two snacks throughout the day. The meals were based on recipes and foods typically eaten in a standard Czech school and home diet, thus, except for portion control, the meals did not represent an adjustment for most participants. Although the participants and their families agree to comply with the diet, potential leftover food and/or additional intake of other items outside the provided meals could not be accounted for. On average, the meals were composed of approximately 17% protein, 28% fat and 55% carbohydrates. This is a study period average, thus daily percentages were different. Participants were not all sampled at the same time, but throughout the study period with the earliest collections taking place after at least one week of habituation to the prescribed diet. As a result of the selection criteria, a similar physical activity regime, a homogenous diet among the participants, and the same ethnic and geographic background of the participants, the effects of cofounding variables were minimized.

The participants‘ body mass index (BMI) standard deviation score (z-score) was derived from age-specific and sex-specific parameters from the Czech National Institute of Public Health [20]. Based on World Health Organization’s guidelines [21], these data were used to classify them into three categories: with obesity (OB) Z-scores > 2.00, with overweight (OW) Z-scores > 1.00, and with normal (N) Z-scores ≤ 1.00 and ≥ -2.00. In total, 16 classified with normal-weight (N), 17 with overweight (OW), and 19 with obesity (OB). Table 1 displays, per each of the three study groups, the size, gender, as well as the mean (± standard deviation) for the age, body mass index (BMI), BMI z-score, and the dietary percent macronutrient composition and kilocalorie content one day prior (D-1) and two days prior (D-2) the date of sampling. S1 Table provides similar data per each participant.

Table 1. Characteristics of the participants per study group (N, OW, OB).

N OW OB p-valuea
n 16 17 19 -
Gender M = 7, F = 9 M = 6, F = 11 M = 11, F = 8 -
Age (years) 11.06 (± 2.46) 11.47 (± 2.24) 10.47 (± 2.37) 0.45
BMI (kg/m2) 18.05 (± 2.45) 23.93 (± 3.10) 30.17 (± 4.28) < 0.01
BMI z-score 0.07 (± 0.80) 1.53 (± 0.29) 2.37 (± 0.23) < 0.01
% Carb. D-1 64.06 (± 5.09) 63.33 (± 3.93) 64.02 (± 4.32) 0.87
% Prot. D-1 18.51 (± 1.70) 19.55 (± 1.68) 19.12 (± 2.07) 0.29
% Fat D-1 17.43 (± 4.93) 17.11 (± 3.12) 16.86 (± 3.78) 0.92
% Carb. D-2 66.46 (± 3.18) 65.13 (± 6.64) 64.96 (± 5.89) 0.69
% Prot. D-2 18.29 (± 4.26) 21.00 (± 3.83) 19.43 (± 2.18) 0.10
% Fat D-2 15.25 (± 3.24) 13.88 (± 4.87) 15.61 (± 4.66) 0.48
kcal D-1 2224.80 (± 309.28) 1574.96 (± 154.58) 1565.42 (± 137.60) < 0.01
kcal D-2 2066.15 (± 322.74) 1533.68 (± 129.93) 1553.61 (± 77.66) < 0.01

M = male, F = female; values reported as mean (± standard deviation); D-1 = one day prior to sampling; D-2 = two days prior to sampling.

a. p-value based on one-way ANOVA test.

Sample collection

Stool sample collection was carried out by the child/adolescents themselves after proper instruction of the use of a disposable kit that consisted of a paper collection surface from which approximately 1 g of stool was collected with a plastic spoon and deposited into a plastic vial. The sample was then given to a nurse and stored at—20 °C until it was transported to the analysis lab where it was stored at -80 °C until the time of the analysis.

After thawing, three stool aliquots of approximately 200 mg were placed into three 1.5 mL microcentrifuge tubes. One aliquot was lyophilized to estimate the water content. No water content was reported for two N samples, and for three OB samples. These values were then used to normalize metabolite concentrations to water content as described in the statistics section. The other two aliquots were used for the NMR (metabolomic) and 16S rDNA sequencing analysis. Metabolomic analysis was applied to all 52 samples while 16S rDNA profiling was carried out in 47 samples due to insufficient sample amount (2 from the N and 3 from the OW group).

Metabolomic analysis

NMR sample preparation and processing

After thawing the aliquot from the 1.5 mL microcentrifuge tube, 600 μL of ultrapure water was added. This was then vortexed (3000 rpm, 10sec) and centrifuged (17000 xg, 10 min) using a fixed angle rotor. The resulting supernatant (540 μL) was transferred to another 1.5 mL microcentrifuge tube, and 60 μL of phosphate buffered saline (PBS, 1.5 M K2HPO4 / 1.5 M NaH2PO4, 5 mM 3-(trimethylsilyl)-2,2,3,3-tetradeuteropropionic acid (TSP) + D2O, 0.2% NaN3, pH 7.4) solution was added. The sample was then centrifuged (17000 xg, 10 min) using a fixed angle rotor. The resulting supernatant (500 to 550 μL) was transferred to a 5 mm NMR tube and introduced into an NMR spectrometer for analysis.

NMR spectroscopy

1H NMR spectra were recorded on a 500.23 MHz Bruker Avance III spectrometer at a temperature of 298 K, equipped with a BBFO SmartProbe with Z-axis gradients and a 24 slot autosampler (Bruker Biospin, Germany). A standard Bruker noesypr1d (90°-t1-90°-dmix-90°-FID) sequence was used to suppress signals from water molecules, where t1 is a 4 μs delay time and dmix is the mixing time (0.1 s). Acquisition parameters for the spectra were 128 scans, a 16 ppm spectral width collected into 32K data points, an acquisition time of 4 s, and an interscan relaxation delay of 5 s. Automatic routine including tuning, 3D shimming, 90°pulse calibration and automatic receiver gain setting was run prior to each sample.

NMR data processing and analysis

The Free Induction Decay (FID) obtained were zero-filled to 64 k, Fourier-transformed, manually phased, and baseline corrected and referenced to TSP:0 ppm using TopSpin 3.1 software (Bruker Biospin, Rheinstetten, Germany).

Multivariate analysis (MVA) was carried out via a chemometric approach. The spectra were further manually phased and baseline corrected manually using Whittaker smoother algorithm in MestreNova NMR Suite software package (Ver. 6.0.2, Mestrelab Research, S.L., Spain). Spectra between δ 9.0–0.0 ppm (excluding the residual water region, δ 5.1–4.6 ppm) were reduced into consecutive, non-overlapping bins (buckets) of equal 0.04 ppm widths. Bins were integrated and normalized based on the total sum of the spectral integral. Unsupervised principal component analysis (PCA), and supervised partial least squares discriminant analysis (PLS-DA) were applied to the normalized bins using MetaboAnalyst 3.0 (http://www.metaboanalyst.ca) [22, 23] under the following parameters: no data filtering, sum normalization, no data transformation, pareto scaling. The PLS-DA model was evaluated using a 10-fold cross-validation.

Univariate analysis (UVA) was carried out using a quantitative (deconvolution) approach. Using Chenomx NMR Suite (version 7.5, Chenomx Inc., Edmonton, Canada), fourier-transformed spectra were subject to line broadening of 0.3 Hz, followed by further phase and baseline manual correction. Metabolites were identified via the Chenomx Profiler library, the Human Metabolome Database (http://www.hmdb.ca), and the literature. The metabolite concentrations in mg/dL from Chenomx were adjusted for the sample dilution. Using the individual sample wet weight (g) the concentrations were converted to mg/g, then normalized by the mean water content of the entire data set, and finally Log2 transformed to prevent the dominance of higher abundance metabolites, to decrease the skewness of the data, and to approximate a more normal distribution. Under the hypothesis that there was no significant difference among the three study groups, a one-way analysis of variance (one-way ANOVA) was applied (p < 0.05, two-tailed) to the Log2 transformed concentrations. The test accounted for Levene’s test for equality of variances and used Tukey’s HSD as a post-hoc procedure. For comparison, the false discovery rate (FDR) was also evaluated. Afterwards, Log 2 transformed concentrations of the resulting significant metabolites, after removal of outliers using Tukey’s method (above and below 1.5*IQR), were evaluated for the presence and direction of a linear relationship between each metabolite pair and with the z-score through a Pearson correlation (p < 0.05). These analyses were carried using R statistical software version 3.6.3. [24].

16S rRNA gene profiling

DNA extraction and qPCR amplification

DNA for 16S rRNA sequencing was extracted from approximately 50–100 mg of unprocessed stool samples using the DNeasy PowerSoil Kit (Qiagen, Germany) per manufacturer’s instructions. Extraction’s control was performed by qPCR amplification targeting the V4 region of the 16S rRNA gene.

Library preparation and 16S rDNA sequencing

Samples were sequenced in duplicates in a single run. The V4 region of the 16S rDNA gene was amplified using tagged primers by Schloss et al. [25]. using the AccuPrime polymerase blend (Invitrogen, USA). The thermal protocol of the PCR reaction was composed of an initial denaturation at 95°C for 5 minutes, followed by 30 cycles of 1) denaturation at 95°C for 15 seconds, 2) primer annealing at 55°C for 30 seconds and 3) elongation at 68°C for 1 minute using slow amplification ramp of 1 °C per second to reduce chimera formation. A mock community, a mixture of known microbial DNA, was processed along with the research samples. The bacterial mock community was an in-house mixture comprising genomic DNA extracted from cultures of following bacteria, mixed in uneven ratios and frozen in suitably sized aliquots: Actinomyces odontolyticus, Burkholderia cepacia, Clostridioides difficile, Enterococcus faecalis, Escherichia coli, Listeria monocytogenes, Prevotella denticola, Pseudomonas aeruginosa, Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus agalactiae, Streptococcus pneumoniae. The correct identification of the genera (or of species, wherever the V4 region is discriminative) was checked upon completion of the sequencing run. Amplicon size was checked by agarose gel electrophoresis. Amplified libraries of the 16S rDNA gene were purified with Ampure magnetic beads on a Biomek robot (both Beckman Coulter, USA). Purified libraries were then equalized, and pooled. Equalization was based on quantification by a real-time PCR assay using the KAPA library quantification kit (Kapa Biosystems, USA). Data from the qPCR machine were processed by a computer script calculating dilution ratios, and the equalization and pooling was run on a Biomek robot (Beckman Coulter, USA). The final concentration of the pools of 16S rRNA libraries was measured by Qubit dsDNA high-sensitivity assay (Thermo Fisher Scientific, USA). Sequencing was performed on a MiSeq instrument (Illumina, USA) with the sequencing kit for 2x 250 base pairs (Ilumina, USA).

16S rDNA data analysis

The ensuing demultiplexed sequencing reads were first trimmed and filtered by quality, dereplicated to remove redundancy, error rates were estimated, and true sequences inferred from the pooled sequencing reads of the whole run. Then the read pairs were merged, chimeras removed, and amplicon sequence variants (i.e. operational taxonomic units) tabulated by samples. Finally, taxonomic assignment was done using the Silva database version 132. These steps were performed using the DADA2 package [26]. The phylogenetic tree was constructed by the neighbour-joining method followed by generalized time-reversible distances with gamma rate variation implemented in the phangorn package [27]. Sequences classified as chloroplasts, archaea, or cyanobacteria were removed. Subsequently, the data were converted into a phyloseq object [28] and analyzed.

Alpha-diversity was compared among the N, OW, and OB groups using the Chao1, Simpson, Shannon, and ACE indices. Comparisons were carried out under the null assumption that there was no significant difference (p < 0.05) among the three groups. These were carried out at the phylum, family, and genus levels via MicrobiomeAnalyst (https://www.microbiomeanalyst.ca) [29, 30] and phyloseq by using the corresponding taxa total abundance after cumulative sum scaling. Due to previously observed association of a high Firmicutes/Bacteroidetes (F/B) ratio with obesity [68], the Ln-transformed F/B ratio derived from the relative abundance of these two phyla was tested under the hypothesis that there was no significant difference among the three study groups via a one-way ANOVA (p < 0.05) with Tukey’s HSD as a post-hoc procedure using R statistical software version 3.6.3. [24]. For the F/B ratio, samples 19 (N), 36 (OW), and 29 (OB) were excluded due to extreme values (≥ 1.5*IQR) in the Bacteroidetes counts.

Due to the controversial nature of differential abundance analysis in microbiome research [31, 32] and that no statistical method can fully capture biological phenomena, differential abundance testing was carried out using two techniques: 1) analysis of composition of microbiomes (ANCOM), which has been shown to provide lower false discovery rate (FDR) than comparable methods [32, 33]; and 2) edgeR, which has also displayed relatively lower FDR (although higher than ANCOM) and has been recommended for overall performance and smaller data sets [3335]. ANCOM was applied to the total abundance table using a significance threshold of ≥ 0.8 and was carried out under the null assumption that among the three different groups there was no significant difference in the relative abundance proportion between each taxon pair at a specific taxonomic level. It was carried out at five taxonomic levels (genus to phylum) using the script ANCOM v2.1 [36] in R statistical software version 3.6.3. [24]. EdgeR (significance p ≤ 0.01 after FDR correction) was carried out under the null hypothesis that taxa were not differentially abundant among the three study groups using MicrobiomeAnalyst under the following parameters: at least 25% of values having a read count of 4 or greater, a variance > 10% by IQR throughout the experiment, and cumulative sum scaling without rarefaction or transformation.

Correlation of metabolomic and 16S rDNA analyses

Resulting significant genera from the differential abundance analysis were evaluated for the presence and direction of a relationship among themselves and with the significant metabolite concentrations and the z-score through a correlation test. This was also done globally for all the identified metabolites and genera. The Spearman correlation test (p < 0.05) was chosen due to the non-normal distribution of the genus level data despite attempted transformations. Due to the challenge of zero values in microbial composition [33, 37], a pseudo-count value of one was added to all read counts, then the relative abundance was derived for analysis. The analysis was carried out using R statistical software version 3.6.3. [24].

Results

Metabolomic analysis

Multivariate analysis (MVA)

PCA did not display clear separation among the N, OW, and OB groups. The supervised approach using PLS-DA also failed to show clear separation. Cross-validation Q2 values were negative regardless of the number of principal components, strongly suggesting that the model lacked predictive power or that it was overfitted. This was attributed to noise in the data and a relative small sample size.

Univariate analysis (UVA)

Sixty-three distinct metabolites were identified through compound deconvolution (Fig 1). One-way ANOVA identified five significantly different compounds among the three groups: butyrate (p = 0.016), arabinose (p = 0.033), galactose (p = 0.036), trimethylamine (TMA) (p = 0.044), and acetate (p = 0.045). After application of Tukey HSD post hoc test all compounds, except for acetate (p = 0.063), showed a significant difference between the N and OB groups and none showed significance between N and OW and between OW and OB groups. All of these compounds had a higher mean concentration in the OB group compared to the N group (Fig 2). Application of the false discovery rate (FDR) for multiple comparisons suggested that only 44% of these five metabolites would be expected to be significant. Given the study’s sample size and not to discard potentially valuable metabolites that may be important for generating further hypotheses, we have included the metabolites identified through the Tukey HSD test in the Discussion section.

Fig 1. Representative 1H NMR spectrum.

Fig 1

63 identified metabolites. Compounds in yellow are the five significantly different (p < 0.05) metabolites based on one-way ANOVA. For visual clarity, with the exception of the five significant metabolites, compounds are only listed once in the spectra regardless of their actual number of spectral peaks. The water region (4.5 to 5.2 ppm) has been excluded.

Fig 2. Metabolite concentration (mg/g) boxplots.

Fig 2

Significantly different (p < 0.05) metabolites among the N, OW, and OB groups based on one-way ANOVA (significance found only between N and OB groups after post-hoc test. Acetate was not significant after application of post-hoc test). The x-axis shows the group name and the mean ± standard deviation. The numbers and text in the graphical area represent: the post-hoc p-value where significant, NS. = not significant, the median and the sample numbers that lie outside the visible range area.

A Pearson correlation of these metabolites between themselves and the z-score showed the following as significant: z-score with arabinose (p = 0.050, correlation coefficient (cc) = 0.31), galactose (p = 0.014, cc = 0.38), and TMA (p = 0.016, cc = 0.34); acetate with butyrate (p < 0.001, cc = 0.73) and TMA (p = 0.004, cc = 0.40); and arabinose with galactose (p < 0.001, cc = 0.67). These all displayed a positive relationship with the strongest correlations between acetate with butyrate, and arabinose with galactose.

16S rDNA analysis

A total of 83 genus, 36 family, 19 order, 15 class, and 6 phylum level taxa were identified. Fig 3 is a heatmap based on the phyla’s relative abundance among the participants in the three study groups. Alpha-diversity assessment at the genus, family, and phylum levels showed no significant differences (all p-values > 0.3) among the N, OW, and OB groups. Likewise, the Firmicutes to Bacteroidetes (F/B) ratio was not significantly different among the three groups by one-way ANOVA testing.

Fig 3. Heatmap based on phyla % relative abundance.

Fig 3

Warmer colors indicate higher % relative abundance, which was exhibited by Bacteroidetes and Firmicutes. Cooler colors indicate lower % relative abundance. Inter-individual variability does not display clear clustering among the three study groups.

Differential abundance analysis through ANCOM did not identify any significant taxa at any of the taxonomic levels, whereas the more permissive EdgeR identified the following suggestive associations: Escherichia (p = 0.005), and Tyzzerella subgroup 3 (p = 0.006) at the genus level; the signal from Escherichia was reflected also at the family level of Enterobacteriaceae (p = 0.009). No differential abundance was noted at the order, class, nor phylum levels. Escherichia is one of the main representatives of Enterobateriaceae [38], and both taxa displayed a similar relative abundance pattern by showing a decrease from the N to the OB group; in contrast, Tyzzerella subgroup 3 showed an increase. Fig 4 shows the genera with the highest relative abundances, as well as Escherichia and Tyzzerella subgroup 3. Fig 5 displays the log10 transformed relative abundance for the two significant genera in the three study groups.

Fig 4. Stacked bar charts based on genera % relative abundance.

Fig 4

Display of the 20 most abundant genera (by relative abundance), as well as the two significant genera (Escherichia and Tyzzerella subgroup 3) by study group. Genus Other represents the aggregate of the remaining 61 identified genera.

Fig 5. Genera relative abundance boxplots.

Fig 5

The two genera that displayed significant difference among the N, OW, and OB groups. The x-axis shows the group name and the mean ± standard deviation, and underneath is the median.

Correlation of metabolomic and 16S rDNA analyses

Spearman correlation of the relative abundance of the significant taxa with the concentration of the significant metabolites and with the z-score did not show any positive significant correlations. Nevertheless, as shown in Table 2, strong positive and negative correlations were observed among other significant metabolites and non-significant genera, as well as the reverse. Fig 6 displays the strength of the positive and negative correlations among all identified genera and metabolites.

Table 2. Significant correlations of the significant metabolites with identified genera.

Genus Butyrate Arabinose Galactose TMA
Blautia 0.425
Butyricicoccus 0.326
Butyricimonas - 0.346
Catenibacterium - 0.364
Coprococcus 1 - 0.481
Coprococcus 3 - 0.303
Desulfovibrio - 0.413 - 0.428
Eggerthella - 0.290
Erysipelotrichaceae UCG-003 0.457 0.450
Fusinibacter 0.409
Haemophilus 0.420
Paraprevotella - 0.300 - 0.311
Parasutterella - 0.301
Romboutsia - 0.339
Roseburia 0.304
Ruminoclostridium 5 - 0.477 - 0.398
Ruminoclostridium 6 - 0.317 - 0.327
Ruminoclostridium 9 - 0.430 - 0.377
Ruminococcaceae NK4A214 - 0.472 - 0.360
Ruminococcaceae UCG-002 - 0.366
Ruminococcaceae UCG-003 - 0.394
Ruminococcaceae UCG-010 - 0.355 - 0.354
Slackia - 0.349

Values are Spearman correlation coefficients. TMA = trimethylamine.

Fig 6. Metabolite-genus spearman correlation heatmap.

Fig 6

The x-axis shows the genera and the y-axis the metabolites. Warmer colors indicate positive correlations. Cooler colors indicate negative correlations. The more intense the color, the closer the number is to the Spearman correlation value 1 or -1.

Discussion

Our results showed an increase of fecal butyrate in the OB compared to the N group, which lends support to previous observations of higher short-chain fatty acid (SCFA) concentrations in children with overweight/obese compared to those who are normal-weight [8, 3941]. An increased SCFA concentration, especially butyrate and acetate, has also been observed in obese mice when compared to their lean counterparts [42]. Two suggested reasons for this are: 1) higher substrate fermentation activity by gut microbiota, which translates into increased microbial energy harvest, and/or 2) decreased absorption due to either low-grade inflammation, more rapid gut transit time, or shifts in microbial cross-feeding patterns [8, 41, 43]. Given that the diet among the participants in our study was, except for portion size (OW and OB consumed, on average, 30% fewer kcal than N), approximately homogenous (approx. 17% protein, 28% fat and 55% carbohydrates), it does suggest higher microbial fermentation activity from fermentative substrates such as resistant starch and dietary fiber, the main sources of microbiota-derived SCFAs [5, 8, 44]. Despite consuming less kcal, the OW and OB groups showed significantly more fecal butyrate, which has been identified as the main energy supplier for colonic epithelial cells [8]. It is common for microbiota produced butyrate to end up in stool when not consumed by the colonic epithelium [8]. It has been estimated that SCFAs contribute about 60–70% of the energy requirements of colonic epithelial cells and 5–15% of the total caloric requirements of humans [45]. A proposed mechanism on how an increase in butyrate and other SCFAs may increase energy harvest is that SCFAs may serve as substrates for hepatic de novo lipogenesis (DNL) [42, 46]. The excess non-metabolized SCFAs reach the liver via the portal system, where they may serve as precursors for gluconeogenesis in case of propionate, and lipogenesis for acetate and butyrate [47, 48]. Goffredo et al. (2016) in a study of 84 youth ranging from non-obese to severely obese observed that the three major SCFAs were positively associated with body and visceral fat, and from these, butyrate was the only one significantly associated with hepatic fat; furthermore, when a subset of this group was tested for associations with DNL, butyrate was significantly associated with a delta increase in hepatic DNL after a controlled dietary carbohydrate load [46]. The same study, using an in vitro stool assay, also observed a higher fermentation capability of fructose by youth with obesity compared to nonobese, which further supports the concept of increased energy harvest from food in those youth with obesity [42, 46]. In looking for the potential instigators of these changes, the gut microbiota, it is important to keep in perspective that the SCFA-producing microbes are a phylogenetically diverse group [45], with a wide distribution of enteric bacteria producing acetate; a much more conservative distribution for butyrate, the most well-known being in the Firmicutes phylum (Faecalibacterium, Eubacterium, Roseburia); and for propionate several Firmicutes, Bacteroidetes, and Proteobacteria phyla such as families Veillonellaceae and Lachnospiraceae [4951]. The two significant taxa in our study, Escherichia and Tyzzerella subgroup 3, were not significantly associated with butyrate; nevertheless, the SCFA was significantly associated with nine genera (Table 2). Butyrate’s two positive correlations, with Haemophilus and Roseburia, are supported by several previous studies [7, 49, 50, 52].

Although the higher concentration of SCFAs in children with overweight/obese in several studies [8, 3941], including butyrate in ours, could suggest them as an obesity biomarker, this is not without controversy given that SCFAs are attributed a myriad of health benefits such as, among others, improvement in blood lipid profiles, glucose homeostasis, and even reduced body weight [7, 53]. How does one reconcile this contradiction? A potential conceptual analogy is that of nutrient overload, a certain nutrient amount may confer benefits, but an excess of it could very well be detrimental. Also, it is important to keep in mind the limitations of each study; for example, the anti-inflammatory effects of butyrate have been studied mainly in vitro [45]. In addition, it may be more beneficial to look for biomarkers as part of a panel of biomarkers instead of individual ones as mentioned by Vignoli et al. (2019) [54].

In addition to SCFAs, monosaccharides arabinose and galactose also had higher concentrations in our OW and OB groups, and the two monosaccharides displayed a strong positive correlation with each other, and both showed a significant positive correlation with the BMI z-score. It appears that most monosaccharides in stool often originate from the non-absorbed breakdown of polysaccharides (resistant starches, dietary fiber), which are the main source of carbon and energy for the gut microbiota [55], or directly from the diet which can be used as nutrition by the host’s enzymes [56]. A higher concentration of arabinose and galactose in the OW and OB groups may suggest an excess of saccharides from the diet or from the breakdown of polysaccharides which are not absorbed due to energy needs being met without them. Given the controlled diet of the participants, the results thus suggest the origin to be the polysaccharide breakdown. This would directly tie in with the concept of an increased energy harvest by the microbial dysbiosis in the obese state [8, 41, 43], which would result in an excess of monosaccharides as well as a higher load of SCFAs.

Trimethylamine (TMA) also showed higher concentrations in the OW and OB groups. It is known to be produced by various gut microbiota taxa from dietary quaternary amines, mainly choline and L-carnitine derived from eggs, milk, liver, red meat, poultry, shell fish and fish [5759]. It’s considered toxic due to its further oxidation into trimethylamine N-oxide (TMAO), which has been associated with atherosclerosis, cardiovascular diseases, and other ailments [57, 59, 60]. In a previous study, children with obesity showed a decrease of TMA in fecal water after a diet intervention consisting of rich amounts of non-digestible carbohydrates [60]. TMA was also shown to be downregulated in the urine of children supplemented with non-digestible carbohydrates [6, 61]. Other diet induced changes included significant weight loss, structural microbiota changes, a reduction of serum antigen load, and alleviation of inflammation [6]. The identified taxa involved in TMA production appear to constitute members of the core gut community, though at very low abundances and characterized by functional redundancies indicating that several taxa potentially contribute to the TMA pool [60]. The majority of these were members of the genus Clostridium XIVa and a specific Eubacterium [60]. This potential is further supported by TMA’s significant positive correlation with acetate (p = 0.004) and the BMI z-score (p = 0.016).

Genera Escherichia (phylum Proteobacteria), and Tyzzerella subgroup 3 (phylum Firmicutes), were not significantly correlated with our significant metabolites, but they were significantly different among the three study groups. In our study, Escherichia decreased in relative abundance from the N to the OB group. The genus includes both commensal and pathogenic species, and although species E.coli has been observed to be increased in children with obesity compared those with normal-weight [62], a general pattern of this genus in relation to childhood obesity is still very open to investigation. With Tyzzerella subgroup 3 we observed a relative abundance increase from the N to the OB group. We could not find any associations between this taxon and obesity in the literature and, overall, this member of Lachnospiraceae appears to be of little medical relevance; nevertheless, it has been reported in connection to dietary variables [63], and one study did observe related genera Tyzzerella and Tyzzerella subgroup 4 to be enriched in a group of adults with higher cardiovascular disease risk when compared to lower-risk subjects [64]. Even though our 16S rDNA analysis only revealed two significantly different genera among the three study groups, it is important to point out, especially for future investigations, that the obese phenotype may be better characterized by the abundance of several distinct communities rather than by the presence of specific species [46]; furthermore, an alteration in efficiency of energy harvest produced by gut bacterial composition changes does not have to be great to contribute to obesity given that small changes in energy balance, over the course of a year, can result in significant changes in body weight [42, 65]. In addition, another possibility is that although inter-group compositional differences may be minimal, the differences observed in our metabolite data could rather indicate differences in bacterial functional activity where metabolically versatile species adapt to changing nutritional circumstances by selectively metabolizing some substrates to the exclusion of others, thus affecting the types and amounts of fermentation products produced from substrates [55]. An apparent change in microbiota functionality, but not in composition, was observed in a study my Morales et al. (2016) where a high-fat diet accompanied by fiber supplementation induced inflammation while not altering gut microbiota composition [66].

In conclusion, our findings suggest support to the hypothesis of increased energy harvest in obesity by the human gut microbiota through the growing observation of increased fecal butyrate in children with overweight/obesity and an increase of certain monosaccharides in the stool. Also supported is butyrate’s positive correlation with Haemophilus and Roseburia, as well as the increase of trimethylamine as an indicator of an unhealthy state.

Supporting information

S1 Table. Characteristics of the 52 participants.

T1 and T2 refer to one and two days prior to the sampling date. The kcal amount is per the entire day.

(XLSX)

Acknowledgments

We warmly thank the study participants and their families, as well as the staff from Olivova Children’s Medical Institution (Olivova Dětská Léčebna), whose support was essential in completing this investigation.

Data Availability

All data files are available from Mendeley Data under the following DOI link: http://dx.doi.org/10.17632/cwj76cbvc9.1. The items included there are: 1) S1 Table 1 (as referenced in the manuscript) containing the individual participant’s gender, age, BMI, BMI z-score, as well as the kilocalorie and macronutrient daily percentage composition one and two days prior to sampling; 2) unrarefied source data for the 16S rRNA gene sequencing analysis; 3) Metabolite concentrations in mg/g derived from Chenomx NMR Suite version 7.5 for each of the 52 study participants; and 4) the 1H NMR spectra for the 52 study participants.

Funding Statement

Funding for this research was provided by the Ministry of Education, Youth and Sports of the Czech Republic, research grants INTER-COST LTC19008 and METROFOOD-CZ research infrastructure project LM2018100, both awarded to JH. The funder website is https://www.msmt.cz/. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

References

  • 1.UNICEF. Children, food and nutrition: growing well in a changing world. 2019.
  • 2.Zhao X, Gang X, Liu Y, Sun C, Han Q, Wang G. Using Metabolomic Profiles as Biomarkers for Insulin Resistance in Childhood Obesity: A Systematic Review. Journal of Diabetes Research. Hindawi Limited; 2016. 10.1155/2016/8160545 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Juonala M, Magnussen CG, Berenson GS, Venn A, Burns TL, Sabin MA, et al. Childhood adiposity, adult adiposity, and cardiovascular risk factors. N Engl J Med. 2011;365: 1876–1885. 10.1056/NEJMoa1010112 [DOI] [PubMed] [Google Scholar]
  • 4.Dietz WH. Health consequences of obesity in youth: Childhood predictors of adult disease. Pediatrics. 1998. pp. 518–525. [PubMed] [Google Scholar]
  • 5.Vernocchi P, Del Chierico F, Putignani L. Gut microbiota profiling: Metabolomics based approach to unravel compounds affecting human health. Front Microbiol. 2016;7. 10.3389/fmicb.2016.01144 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Zhang C, Yin A, Li H, Wang R, Wu G, Shen J, et al. Dietary Modulation of Gut Microbiota Contributes to Alleviation of Both Genetic and Simple Obesity in Children. EBioMedicine. 2015;2: 968–984. 10.1016/j.ebiom.2015.07.007 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Álvarez-Mercado AI, Navarro-Oliveros M, Robles-Sánchez C, Plaza-Díaz J, Sáez-Lara MJ, Muñoz-Quezada S, et al. Microbial population changes and their relationship with human health and disease. Microorganisms. 2019;7. 10.3390/microorganisms7030068 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Riva A, Borgo F, Lassandro C, Verduci E, Morace G, Borghi E, et al. Pediatric obesity is associated with an altered gut microbiota and discordant shifts in Firmicutes populations. Environ Microbiol. 2017;19: 95–105. 10.1111/1462-2920.13463 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Ley RE, Bäckhed F, Turnbaugh P, Lozupone CA, Knight RD, Gordon JI. Obesity alters gut microbial ecology. Proc Natl Acad Sci U S A. 2005;102: 11070–11075. 10.1073/pnas.0504978102 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Le Chatelier E, Nielsen T, Qin J, Prifti E, Hildebrand F, Falony G, et al. Richness of human gut microbiome correlates with metabolic markers. Nature. 2013;500: 541–546. 10.1038/nature12506 [DOI] [PubMed] [Google Scholar]
  • 11.Radjabzadeh D, Boer CG, Beth SA, van der Wal P, Kiefte-De Jong JC, Jansen MAE, et al. Diversity, compositional and functional differences between gut microbiota of children and adults. Sci Rep. 2020;10: 1–13. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Zierer J, Jackson MA, Kastenmüller G, Mangino M, Long T, Telenti A, et al. The fecal metabolome as a functional readout of the gut microbiome. Nat Genet. 2018;50: 790–795. 10.1038/s41588-018-0135-7 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Marcobal A, Kashyap PC, Nelson TA, Aronov PA, Donia MS, Spormann A, et al. A metabolomic view of how the human gut microbiota impacts the host metabolome using humanized and gnotobiotic mice. ISME J. 2013;7: 1933–1943. 10.1038/ismej.2013.89 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Larive C, Barding G, Dinges M. NMR spectroscopy for metabolomics and metabolic profiling. Anal Chem. 2015;87: 133–146. 10.1021/ac504075g [DOI] [PubMed] [Google Scholar]
  • 15.Markley J, Brüschweiler R, Edison A, Eghbalnia H, Powers R, Raftery D, et al. The future of NMR-based metabolomics. Curr Opin Biotechnol. 2017;43: 34–40. 10.1016/j.copbio.2016.08.001 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Zhang A, Sun H, Wang P, Han Y, Wang X. Modern analytical techniques in metabolomics analysis. Analyst. 2012;137: 293–300. 10.1039/c1an15605e [DOI] [PubMed] [Google Scholar]
  • 17.Rangel-Huerta OD, Pastor-Villaescusa B, Gil A. Are we close to defining a metabolomic signature of human obesity? A systematic review of metabolomics studies. Metabolomics. Springer US; 2019. 10.1007/s11306-019-1553-y [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Newgard CB, An J, Bain JR, Muehlbauer MJ, Stevens RD, Lien LF, et al. A Branched-Chain Amino Acid-Related Metabolic Signature that Differentiates Obese and Lean Humans and Contributes to Insulin Resistance. Cell Metab. 2009;9: 311–326. 10.1016/j.cmet.2009.02.002 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Santoru ML, Piras C, Murgia A, Palmas V, Camboni T, Liggi S, et al. Cross sectional evaluation of the gut-microbiome metabolome axis in an Italian cohort of IBD patients. Sci Rep. 2017;7: 1–14. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Státní zdravotní ústav (Czech National Institute of Public Health). Hodnocení růstu a vývoje dětí a mládeže, SZÚ (Evaluation of growth and development of children and youth, SZÚ). 2006. http://www.szu.cz/publikace/data/rustove-grafy
  • 21.WHO | BMI-for-age (5–19 years). WHO. 2019.
  • 22.Chong J, Yamamoto M, Xia J. MetaboAnalystR 2.0: From Raw Spectra to Biological Insights. Metabolites. 2019;9: 57. 10.3390/metabo9030057 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Chong J, Wishart DS, Xia J. Using MetaboAnalyst 4.0 for Comprehensive and Integrative Metabolomics Data Analysis. Curr Protoc Bioinforma. 2019;68. 10.1002/cpbi.86 [DOI] [PubMed] [Google Scholar]
  • 24.R Core Team (2020). R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. URL https://www.R-project.org/.
  • 25.Kozich JJ, Westcott SL, Baxter NT, Highlander SK, Schloss PD. Development of a dual-index sequencing strategy and curation pipeline for analyzing amplicon sequence data on the miseq illumina sequencing platform. Appl Environ Microbiol. 2013;79: 5112–5120. 10.1128/AEM.01043-13 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Callahan BJ, McMurdie PJ, Rosen MJ, Han AW, Johnson AJA, Holmes SP. DADA2: High-resolution sample inference from Illumina amplicon data. Nat Methods. 2016;13: 581–583. 10.1038/nmeth.3869 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Schliep KP. phangorn: phylogenetic analysis in R. Bioinforma Appl NOTE. 2011;27: 592–593. 10.1093/bioinformatics/btq706 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.McMurdie PJ, Holmes S. Phyloseq: An R Package for Reproducible Interactive Analysis and Graphics of Microbiome Census Data. PLoS One. 2013;8. 10.1371/journal.pone.0061217 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Dhariwal A, Chong J, Habib S, King IL, Agellon LB, Xia J. MicrobiomeAnalyst: a web-based tool for comprehensive statistical, visual and meta-analysis of microbiome data. Nucleic Acids Res. 2017;45: W180–W188. 10.1093/nar/gkx295 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Chong J, Liu P, Zhou G, Xia J. Using MicrobiomeAnalyst for comprehensive statistical, functional, and meta-analysis of microbiome data. Nat Protoc. 2020;15: 799–821. 10.1038/s41596-019-0264-1 [DOI] [PubMed] [Google Scholar]
  • 31.Morton JT, Marotz C, Washburne A, Silverman J, Zaramela LS, Edlund A, et al. Establishing microbial composition measurement standards with reference frames. Nat Commun. 2019;10: 1–11. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Mandal S, Van Treuren W, White RA, Eggesbø M, Knight R, Peddada SD. Analysis of composition of microbiomes: a novel method for studying microbial composition. Microb Ecol Heal Dis. 2015;26. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Weiss S, Xu ZZ, Peddada S, Amir A, Bittinger K, Gonzalez A, et al. Normalization and microbial differential abundance strategies depend upon data characteristics. Microbiome. 2017;5. 10.1186/s40168-017-0237-y [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Thorsen J, Brejnrod A, Mortensen M, Rasmussen MA, Stokholm J, Al-Soud WA, et al. Large-scale benchmarking reveals false discoveries and count transformation sensitivity in 16S rRNA gene amplicon data analysis methods used in microbiome studies. Microbiome. 2016;4: 62. 10.1186/s40168-016-0208-8 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Jonsson V, Österlund T, Nerman O, Kristiansson E. Statistical evaluation of methods for identification of differentially abundant genes in comparative metagenomics. BMC Genomics. 2016;17: 78. 10.1186/s12864-016-2386-y [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.ANCOM v2.1.
  • 37.Friedman J, Alm EJ. Inferring Correlation Networks from Genomic Survey Data. PLoS Comput Biol. 2012;8: e1002687. 10.1371/journal.pcbi.1002687 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Li L. Infectious Microecology. Advanced Topics in Science and Technology in China. Springer; 2014. pp. 1–22. 10.1007/978-3-662-43883-1_1 [DOI] [Google Scholar]
  • 39.Murugesan S, Nirmalkar K, Hoyo-Vadillo C, García-Espitia M, Ramírez-Sánchez D, García-Mena J. Gut microbiome production of short-chain fatty acids and obesity in children. European Journal of Clinical Microbiology and Infectious Diseases. Springer Verlag; 2018. pp. 621–625. 10.1007/s10096-017-3143-0 [DOI] [PubMed] [Google Scholar]
  • 40.Lu Y, Fan C, Li P, Lu Y, Chang X, Qi K. Short chain fatty acids prevent high-fat-diet-induced obesity in mice by regulating g protein-coupled receptors and gut Microbiota. Sci Rep. 2016;6. 10.1038/srep37589 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41.Schwiertz A, Taras D, Schäfer K, Beijer S, Bos NA, Donus C, et al. Microbiota and SCFA in Lean and Overweight Healthy Subjects. Obesity. 2010;18: 190–195. 10.1038/oby.2009.167 [DOI] [PubMed] [Google Scholar]
  • 42.Turnbaugh P. J., Ley R. E., Mahowald M. A., Magrini V., Mardis E. R. Gordon J. I. et al. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature. 2006;444: 1027–1031. 10.1038/nature05414 [DOI] [PubMed] [Google Scholar]
  • 43.Payne AN, Chassard C, Zimmermann M, Müller P, Stinca S, Lacroix C. The metabolic activity of gut microbiota in obese children is increased compared with normal-weight children and exhibits more exhaustive substrate utilization. Nutr Diabetes. 2011;1: e12–e12. 10.1038/nutd.2011.8 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 44.Kallus SJ, Brandt LJ. The intestinal microbiota and obesity. Journal of Clinical Gastroenterology. 2012. pp. 16–24. 10.1097/MCG.0b013e31823711fd [DOI] [PubMed] [Google Scholar]
  • 45.Brahe LK, Astrup A, Larsen LH. Is butyrate the link between diet, intestinal microbiota and obesity-related metabolic diseases? 2013; 1–10. [DOI] [PubMed] [Google Scholar]
  • 46.Goffredo M, Mass K, Parks EJ, Wagner DA, McClure EA, Graf J, et al. Role of gut microbiota and short chain fatty acids in modulating energy harvest and fat partitioning in youth. J Clin Endocrinol Metab. 2016;101: 4367–4376. 10.1210/jc.2016-1797 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 47.Oliphant K, Allen-Vercoe E. Macronutrient metabolism by the human gut microbiome: Major fermentation by-products and their impact on host health. Microbiome. 2019;7: 1–15. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 48.Morrison DJ, Preston T. Formation of short chain fatty acids by the gut microbiota and their impact on human metabolism. Gut Microbes. 2016;7: 189–200. 10.1080/19490976.2015.1134082 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 49.Ríos-Covián D, Ruas-Madiedo P, Margolles A, Gueimonde M, De los Reyes-Gavilán CG, Salazar N. Intestinal short chain fatty acids and their link with diet and human health. Frontiers in Microbiology. Frontiers Media S.A.; 2016. 10.3389/fmicb.2016.00185 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 50.Louis P, Hold GL, Flint HJ. The gut microbiota, bacterial metabolites and colorectal cancer. Nature Reviews Microbiology. Nature Publishing Group; 2014. pp. 661–672. 10.1038/nrmicro3344 [DOI] [PubMed] [Google Scholar]
  • 51.Flint HJ, Duncan SH, Scott KP, Louis P. Links between diet, gut microbiota composition and gut metabolism. Proceedings of the Nutrition Society. Cambridge University Press; 2014. pp. 13–22. 10.1017/S0029665114001463 [DOI] [PubMed] [Google Scholar]
  • 52.de la Cuesta-Zuluaga J, Mueller NT, Álvarez-Quintero R, Velásquez-Mejía EP, Sierra JA, Corrales-Agudelo V, et al. Higher fecal short-chain fatty acid levels are associated with gut microbiome dysbiosis, obesity, hypertension and cardiometabolic disease risk factors. Nutrients. 2019;11. 10.3390/nu11010051 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 53.Hjorth MF, Zohar Y, Hill JO, Astrup A. Personalized Dietary Management of Overweight and Obesity Based on Measures of Insulin and Glucose. Annu Rev Nutr. 2018;38: 245–272. 10.1146/annurev-nutr-082117-051606 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 54.Vignoli A, Ghini V, Meoni G, Licari C, Takis PG, Tenori L, et al. High-Throughput Metabolomics by 1D NMR. Angew Chemie—Int Ed. 2019;58: 968–994. 10.1002/anie.201804736 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 55.Macfarlane GT, Macfarlane S. Bacteria, colonic fermentation, and gastrointestinal health. J AOAC Int. 2012;95: 50–60. 10.5740/jaoacint.sge_macfarlane [DOI] [PubMed] [Google Scholar]
  • 56.Hansen NW, Sams A. The microbiotic highway to health—New perspective on food structure, gut microbiota, and host inflammation. Nutrients. MDPI AG; 2018. 10.3390/nu10111590 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 57.Wang Z, Klipfell E, Bennett BJ, Koeth R, Levison BS, Dugar B, et al. Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. Nature. 2011;472: 57–65. 10.1038/nature09922 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 58.Zeisel SH, Mar M-H, Howe JC, Holden JM. Concentrations of Choline-Containing Compounds and Betaine in Common Foods. J Nutr. 2003;133: 1302–1307. 10.1093/jn/133.5.1302 [DOI] [PubMed] [Google Scholar]
  • 59.Blaak EE, Canfora EE. Increased circulating choline, L-carnitine and TMAO levels are related to changes in adiposity during weight loss: role of the gut microbiota? Ann Transl Med. 2018;6: S92–S92. 10.21037/atm.2018.11.11 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 60.Rath S, Heidrich B, Pieper DH, Vital M. Uncovering the trimethylamine-producing bacteria of the human gut microbiota. Microbiome. 2017;5: 1–14. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 61.Yan S, Huang J, Chen Z, Jiang Z, Li X, Chen Z. Metabolomics in gut microbiota: applications and challenges. Sci Bull. 2016;61: 1151–1153. 10.1007/s11434-016-1142-7 [DOI] [Google Scholar]
  • 62.Gao X, Jia R, Xie L, Kuang L, Feng L, Wan C. Obesity in school-aged children and its correlation with Gut E.coli and Bifidobacteria: A case-control study. BMC Pediatr. 2015;15. 10.1186/s12887-015-0384-x [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 63.Liu Y, Ajami N, El-Serag H, Hair C, Graham D, White D. Dietary quality and the colonic mucosa-associated gut microbiome in humans. Am J Clin Nutr. 2019;110: 701–712. 10.1093/ajcn/nqz139 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 64.Kelly TN, Bazzano LA, Ajami NJ, He H, Zhao J, Petrosino JF, et al. Gut Microbiome Associates with Lifetime Cardiovascular Disease Risk Profile among Bogalusa Heart Study Participants. Circ Res. 2016;119: 956–964. 10.1161/CIRCRESAHA.116.309219 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 65.Flegal KM, Troiano RP. Changes in the distribution of body mass index of adults and children in the US population. Int J Obes. 2000;24: 807–818. 10.1038/sj.ijo.0801232 [DOI] [PubMed] [Google Scholar]
  • 66.Morales P, Fujio S, Navarrete P, Ugalde JA, Magne F, Carrasco-Pozo C, et al. Impact of Dietary Lipids on Colonic Function and Microbiota: An Experimental Approach Involving Orlistat-Induced Fat Malabsorption in Human Volunteers. Clin Transl Gastroenterol. 2016;7: e161. 10.1038/ctg.2016.20 [DOI] [PMC free article] [PubMed] [Google Scholar]

Decision Letter 0

Suzanne L Ishaq

26 Oct 2020

PONE-D-20-27287

Stool metabolome-microbiota evaluation among children and adolescents with obesity, overweight, and normal-weight using 1H NMR and 16S rRNA gene profiling

PLOS ONE

Dear Dr. Jaimes,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Both reviewers agreed that more or somewhat different analysis could benefit the manuscript.  I agree with reviewer 1's concerns about the specific components of the different diets, and the nuance that is creating in microbiomes by nutrient type, bioavailability, and preparation effects.  I encourage the authors to provide significantly more detail on the diets to address this point.

Reviewer 2 suggested additional citations, which were accidentally omitted in their submitted review.  These include:

Shankar, V., Homer, D., Rigsbee, L. et al. The networks of human gut microbe–metabolite associations are different between health and irritable bowel syndrome. ISME J 9, 1899–1903 (2015). https://doi.org/10.1038/ismej.2014.258

and

   Cribbs, S.K., Uppal, K., Li, S. et al. Correlation of the lung microbiota with metabolic profiles in bronchoalveolar lavage fluid in HIV infection. Microbiome 4, 3 (2016). https://doi.org/10.1186/s40168-016-0147-4

Please submit your revised manuscript by Dec 10 2020 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols

We look forward to receiving your revised manuscript.

Kind regards,

Suzanne L. Ishaq, PhD

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. We note that you have stated that you will provide repository information for your data at acceptance. Should your manuscript be accepted for publication, we will hold it until you provide the relevant accession numbers or DOIs necessary to access your data. If you wish to make changes to your Data Availability statement, please describe these changes in your cover letter and we will update your Data Availability statement to reflect the information you provide.

3. In your Methods section, please provide additional information about the participant recruitment method and the demographic details of your participants. Please ensure you have provided sufficient details to replicate the analyses such as: a) the recruitment date range (month and year), b) a description of any inclusion/exclusion criteria that were applied to participant recruitment, c) a table of relevant demographic details, c) a description of how participants were recruited.

4.  We suggest you thoroughly copyedit your manuscript for language usage, spelling, and grammar. If you do not know anyone who can help you do this, you may wish to consider employing a professional scientific editing service.  

Whilst you may use any professional scientific editing service of your choice, PLOS has partnered with both American Journal Experts (AJE) and Editage to provide discounted services to PLOS authors. Both organizations have experience helping authors meet PLOS guidelines and can provide language editing, translation, manuscript formatting, and figure formatting to ensure your manuscript meets our submission guidelines. To take advantage of our partnership with AJE, visit the AJE website (http://learn.aje.com/plos/) for a 15% discount off AJE services. To take advantage of our partnership with Editage, visit the Editage website (www.editage.com) and enter referral code PLOSEDIT for a 15% discount off Editage services.  If the PLOS editorial team finds any language issues in text that either AJE or Editage has edited, the service provider will re-edit the text for free.

Upon resubmission, please provide the following:

●      The name of the colleague or the details of the professional service that edited your manuscript

●      A copy of your manuscript showing your changes by either highlighting them or using track changes (uploaded as a *supporting information* file)

●      A clean copy of the edited manuscript (uploaded as the new *manuscript* file)

5. Please provide a sample size and power calculation in the Methods, or discuss the reasons for not performing one before study initiation.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Partly

Reviewer #2: Yes

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: Yes

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: No

Reviewer #2: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: Summary – This study examines associations between microbial taxa, based on 16S rRNA sequencing, and the stool metabolome, via 1H NMR, in normal, overweight, and obese individuals. While interesting, the associations of both microbial taxonomy and metabolites with obesity is well described in the literature. This manuscript offers no new concepts, and significant issues must be addressed.

Conceptual/Major Comments –

1. Given the focus on obesity, metabolites, and diet, the description of diet in this study is lacking on multiple levels.

a. The statement that diet was controlled in this study by simply balancing macronutrients (fats, carbohydrates, and protein) is a misleading overstatement. Given these constraints, one subject could have eaten simple carbohydrates (e.g., highly processed white bread) and another subject could have eaten an equivalent caloric percentage of carbohydrates of completely complex carbohydrates (e.g., fruits, vegetables), and these would be considered the same; however, these diets would lead to extremely different microbiota and metabolomes.

b. Additionally, there is no description of calorie controls beyond the statement that “the children with obese/overweight on a caloric restriction”. Given that half of the metabolites identified (arabinose, galactose) are found in food and do not require transformation by microbial metabolism, a highly plausible explanation is that subjects in the OW and OB groups consumed more food that resulted in the higher amounts of arabinose and galactose in the stool. If diet is to be considered in this manuscript, there must be a complete explanation and analysis of diet as a co-factor.

2. The control group (normal weight) is a group that was receiving treatment of respiratory or locomotive conditions. Individuals with underlying and potentially confounding conditions should not be used as controls.

3. A complete description, or reference, is needed to describe the mock community used as a reference.

4. The relationship between gut microbiome and obesity has been examined extensively in many studies with large sample sizes. For a summary see:

Sze, M.A. and Schloss, P.D., 2016. Looking for a signal in the noise: revisiting obesity and the microbiome. MBio, 7(4), pp.e01018-16. Additional validation of these trends is not needed.

The same holds for the SCFA connection, for example

Schwiertz, A., Taras, D., Schäfer, K., Beijer, S., Bos, N.A., Donus, C. and Hardt, P.D., 2010. Microbiota and SCFA in lean and overweight healthy subjects. Obesity, 18(1), pp.190-195.

Kim, K. N., Yao, Y., & Ju, S. Y. (2019). Short Chain Fatty Acids and Fecal Microbiota Abundance in Humans with Obesity: A Systematic Review and Meta-Analysis. Nutrients, 11(10), 2512. https://doi.org/10.3390/nu11102512

The authors should consider refocusing the analyses on the age of the subjects (most studies have been conducted in adults) and/or additional types of analyses that have not been previously conducted.

5. Speculations regarding mechanisms (i.e., increased energy harvest) are lacking support and should be revised.

6. Please consider changing the type of figure used to display taxonomic abundance (Figure 4). The pie charts currently used are an ineffective and inaccurate method of representing the data, as they do not include any display of variance. Consider using a heatmap to show intersubject variability. Additionally, the Firmicutes/Bacteroidetes appear to be incorrect based on the data presented in this figure (N – 50.4/34.1 = 1.48, not 2.2; OW – 57.9/28.7 = 2.02, not 3.4; OB – 59.3/26.2 = 2.26, not 5.7).

7. Tukey’s HSD provides weak control of Type I error. Please consider using false discovery rate to correct for multiple comparisons in this type of exploratory study.

Reviewer #2: In this article the authors aim to show a difference in stool microbiome bacterial composition and metabolomic profile between children with normal, overweight, and obese BMI z-scores. They also attempted to relate the bacterial relative abundance with the metabolite abundance. Among the bacterial composition, the authors find 2 “suggestive associations” (I really like this wording): decreased Escherichia in the obese group compared to the normal group, and increased Tyzzerella subgroup 3 in the obese group compared to the normal group. Among the metabolites, the authors find 5 that are significantly higher in the obese group than the normal group: butyrate, arabinose, galactose, trimethylamine, and acetate. These increased metabolites support for the hypothesis that the gut microbiome in obese people has increased energy harvest compared to people of normal weight.

Overall, the authors have a well designed and appropriately analyzed study that further supports the increased energy hypothesis that others have put forth. I found the discussion of the controversy around higher SCFAs as a biomarker (lines 333-342) particularly clear and helpful. I have a couple of suggestions that would improve the manuscript and some minor concerns that I would like to see addressed before publication.

Major Suggestions:

I would like to see a more sophisticated analysis to find associations between microbes and metabolites. The authors only examined microbes and metabolites that were significantly different across BMI groups for positive Spearman correlations (page 12, line 313). An analysis that includes all metabolites and bacteria could reveal other patterns that differ across BMI groups; examples include correlations (seen in Shankar, et al) and sparse partial least squares regression (seen in Cribbs, et al).

You refer to the microbiome but only examined bacteria. A discussion that includes other microbes, or the caveat that only bacteria were examined, would widen the audience and appeal of the study.

Minor Concerns:

Lines 77-81: The sentence that starts “For example” is difficult to read and should be simplified to avoid having so many lists in one sentence.

The correlations between metabolites (lines 175-178, 276-284, and fig 3) doesn’t seem to add anything and I would suggest removing it.

Line 211 - When you removed cyanobacteria, were these all cyanobacteria or only those that could not be classified further (potentially indicating non-bacterial origins)? If the latter, please specify.

Line 237 - There’s an extra comma between “or greater” and “a variance >10%”.

Line 340 - This is the second sentence in a row to start with “Also”. Consider using “Finally”, another transition word, or nothing at all.

Line 345 - I would suggest you move the reference to Fig 3 to after “with each other” which is what is displayed in the figure - if you decide to keep it, see above.

Line 370 - Please specify that it is BMI z-score.

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: Yes: Elliot S Friedman

Reviewer #2: Yes: Laura Tipton

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

PLoS One. 2021 Mar 25;16(3):e0247378. doi: 10.1371/journal.pone.0247378.r002

Author response to Decision Letter 0


27 Nov 2020

Response to reviewers.

Reviewer 1:

Comment:

1. Given the focus on obesity, metabolites, and diet, the description of diet in this study is lacking on multiple levels.

a. The statement that diet was controlled in this study by simply balancing macronutrients (fats, carbohydrates, and protein) is a misleading overstatement. Given these constraints, one subject could have eaten simple carbohydrates (e.g., highly processed white bread) and another subject could have eaten an equivalent caloric percentage of carbohydrates of completely complex carbohydrates (e.g., fruits, vegetables), and these would be considered the same; however, these diets would lead to extremely different microbiota and metabolomes.

Response:

We agree with your comment and have now provided more detailed information about the diet that the participants followed. The composition of the meals among the participants was similar (similar ingredients, similar dishes); for example, the carbohydrate portion of each meal was of the same food item, differing only in the portion size based on the subject’s age, gender, and weight. This information has now been more explicitly stated in the methods subsection “Study participants.” Additionally, new information includes the macronutrient percentage intake per each of the three groups (normal, overweight, obese) one and two days prior to sampling (Table 1), as well as per each of the participants (S1 Table 1). This has now been more clearly stated (lines 127-133).

Comment:

b. Additionally, there is no description of calorie controls beyond the statement that “the children with obese/overweight on a caloric restriction”. Given that half of the metabolites identified (arabinose, galactose) are found in food and do not require transformation by microbial metabolism, a highly plausible explanation is that subjects in the OW and OB groups consumed more food that resulted in the higher amounts of arabinose and galactose in the stool. If diet is to be considered in this manuscript, there must be a complete explanation and analysis of diet as a co-factor.

Response:

We have now explicitly stated that those with overweight/obesity were in a 30 % caloric restriction (lines 129-130). Additionally, daily kilocalorie intake per each of the three groups (normal, overweight, obese) one and two days prior to sampling (Table 1), as well as per each of the participants (S1 table 1), has now been included. The diet has been more clearly presented through these tables and in the methods section (lines 127-133). We believe that the new provided information more accurately reflects the consideration of diet as a co-factor and the potential bias it may introduce in the interpretation.

Comment:

The control group (normal weight) is a group that was receiving treatment of respiratory or locomotive conditions. Individuals with underlying and potentially confounding conditions should not be used as controls.

Response:

We agree that the control group (normal-weight youth) may not be an ideal control group; however, given the selection criteria, we still believe that they represent a valuable comparison group. The controls with a respiratory disease were in remission of their condition, and those with an orthopedic (locomotive) diagnoses were healthy enough to take part in the program’s physical activity regime. In addition, the recruitment criterion was no antibiotics in the past three months prior to program participation, none were taking medications, and all were physically able to take part in a physical activity program. Furthermore, except for portion size, they all received a similar diet (same ingredients, same dishes). As a result of the selection criteria, a similar physical activity regime, a homogenous diet among the participants, and the same ethnic and geographic background of the participants, the effect of cofounding variables was minimized. Consequently, we believe that the observations from our study are relevant in contrasting the metabolomic and gut microbiota differences among the three groups (normal-weight, overweight, obese) in children/adolescents. The section describing this (lines 113-135) has been updated to provide these and further details.

Comment:

A complete description, or reference, is needed to describe the mock community used as a reference.

Response:

Further details have been provided to describe all the participants, including the controls. (lines 113-135, Table 1, S1 Table 1)

Comment:

The relationship between gut microbiome and obesity has been examined extensively in many studies with large sample sizes. For a summary see:

Sze, M.A. and Schloss, P.D., 2016. Looking for a signal in the noise: revisiting obesity and the microbiome. MBio, 7(4), pp.e01018-16. Additional validation of these trends is not needed.

The same holds for the SCFA connection, for example

Schwiertz, A., Taras, D., Schäfer, K., Beijer, S., Bos, N.A., Donus, C. and Hardt, P.D., 2010. Microbiota and SCFA in lean and overweight healthy subjects. Obesity, 18(1), pp.190-195.

Kim, K. N., Yao, Y., & Ju, S. Y. (2019). Short Chain Fatty Acids and Fecal Microbiota Abundance in Humans with Obesity: A Systematic Review and Meta-Analysis. Nutrients, 11(10), 2512. https://doi.org/10.3390/nu11102512

The authors should consider refocusing the analyses on the age of the subjects (most studies have been conducted in adults) and/or additional types of analyses that have not been previously conducted.

Response:

Although it has been examined, the findings are still far from being established. There is ample room for expansion and provide a more complete and precise picture of the metabolomic-gut bacteria changes involved.

In regard to focusing the analyses on the age of the subjects, that is actually one of our aims since, as you mentioned, most students have been focused on adults. To express this aim more explicitly, we have revised the text (lines 65, 75-77, 87-91). This included the addition of an additional citation (Radjabzadeh D, Boer CG, Beth SA, van der Wal P, Kiefte-De Jong JC, Jansen MAE, et al. Diversity, compositional and functional differences between gut microbiota of children and adults. Sci Rep. 2020;10: 1–13. doi:10.1038/s41598-020-57734-z).

Comment:

Speculations regarding mechanisms (i.e., increased energy harvest) are lacking support and should be revised.

Response:

We have elaborated the Discussion section to provide more support for the increased energy harvest mechanism in lines 374-376 as well as other details throughout this section. We do attempt to make it clear in our writing that this is still a proposed mechanism. Several citations (some previously in the manuscript and some new additions) support this mechanism. (Turnbaugh P. J., Ley R. E., Mahowald M. A., Magrini V., Mardis E. R. GJI. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature. 2006;444: 1027–1022. doi:10.1007/s11837-013-0766-1), (Goffredo M, Mass K, Parks EJ, Wagner DA, McClure EA, Graf J, et al. Role of gut microbiota and short chain fatty acids in modulating energy harvest and fat partitioning in youth. J Clin Endocrinol Metab. 2016;101: 4367–4376. doi:10.1210/jc.2016-1797), (Oliphant K, Allen-Vercoe E. Macronutrient metabolism by the human gut microbiome: Major fermentation by-products and their impact on host health. Microbiome. 2019;7: 1–15. doi:10.1186/s40168-019-0704-8), (Morrison DJ, Preston T. Formation of short chain fatty acids by the gut microbiota and their impact on human metabolism. Gut Microbes. 2016;7: 189–200. doi:10.1080/19490976.2015.1134082), (Riva A, Borgo F, Lassandro C, Verduci E, Morace G, Borghi E, et al. Pediatric obesity is associated with an altered gut microbiota and discordant shifts in Firmicutes populations. Environ Microbiol. 2017;19: 95–105. doi:10.1111/1462-2920.13463), (Schwiertz A, Taras D, Schäfer K, Beijer S, Bos NA, Donus C, et al. Microbiota and SCFA in Lean and Overweight Healthy Subjects. Obesity. 2010;18: 190–195. doi:10.1038/oby.2009.167), (Payne AN, Chassard C, Zimmermann M, Müller P, Stinca S, Lacroix C. The metabolic activity of gut microbiota in obese children is increased compared with normal-weight children and exhibits more exhaustive substrate utilization. Nutr Diabetes. 2011;1: e12–e12. doi:10.1038/nutd.2011.8).

Comment:

Please consider changing the type of figure used to display taxonomic abundance (Figure 4). The pie charts currently used are an ineffective and inaccurate method of representing the data, as they do not include any display of variance. Consider using a heatmap to show intersubject variability. Additionally, the Firmicutes/Bacteroidetes appear to be incorrect based on the data presented in this figure (N – 50.4/34.1 = 1.48, not 2.2; OW – 57.9/28.7 = 2.02, not 3.4; OB – 59.3/26.2 = 2.26, not 5.7).

Response:

We followed your suggestion and have replaced this figure with that of a heat map to better display inter-individual variability. Since there was no significant difference among the three groups, the percentages from the previous figure were excluded in this figure. The previous Firmicutes/Bacteroidetes discrepancy was due to a calculation that included the outliers that had been excluded in the previous figure.

Comment:

Tukey’s HSD provides weak control of Type I error. Please consider using false discovery rate to correct for multiple comparisons in this type of exploratory study.

Response:

We have considered this and did notice that our significant metabolites were significant at a false discovery rate of 0.56, which means that we would expect 44 % of the identified metabolites to be significant, except that it is hard to ascertain which ones. Since it is an exploratory study, we would like to keep our current methodology as to not potentially discard valuable metabolites. Other researchers may find this important for generating further hypotheses.

Reviewer 2:

Comment:

I would like to see a more sophisticated analysis to find associations between microbes and metabolites. The authors only examined microbes and metabolites that were significantly different across BMI groups for positive Spearman correlations (page 12, line 313). An analysis that includes all metabolites and bacteria could reveal other patterns that differ across BMI groups; examples include correlations (seen in Shankar, et al). The sparse partial least squares regression (seen in Cribbs, et al)

Response:

We believe that you raise a very important point, and we also agree that an analysis that includes all metabolites and genera would be very valuable to report. We consulted both of the examples you provided, and we proceeded with a Spearman correlation analysis similar to what we had initially done; however, we now included all metabolites and genera detected and have displayed these correlations in the form of a heatmap (Fig 5) in the results subsection “Correlation of metabolomic and 16S rDNA analyses.” Consequently, we have also added some material both in the results and discussion sections.

Comment:

You refer to the microbiome but only examined bacteria. A discussion that includes other microbes, or the caveat that only bacteria were examined, would widen the audience and appeal of the study.

Response:

We have edited our language throughout the paper to reflect that only bacteria were examined. We still kept the same title, but throughout the text we believe that it is now clearer that we specifically examined bacteria. We agree that the appeal would be widened by including microbiota outside of bacteria; however, our 16s analysis results are better suited to report and focus only on bacteria for this study.

Comment:

Lines 77-81: The sentence that starts “For example” is difficult to read and should be simplified to avoid having so many lists in one sentence.

Response:

A slight modification of the sentence was made (now line 83-85)

Comment:

The correlations between metabolites (lines 175-178, 276-284, and fig 3) doesn’t seem to add anything and I would suggest removing it.

Response:

We agree with this suggestion and have removed the figure. We are now reporting the correlation coefficients from the figure in written form in lines 311-316.

Comment:

Line 211 - When you removed cyanobacteria, were these all cyanobacteria or only those that could not be classified further (potentially indicating non-bacterial origins)? If the latter, please specify.

Response:

We removed all identifiable cyanobacteria signal. Its overall share on the total bacteriome was negligible, only 0.077 % reads. It originated from 5 samples, with the largest signal being 2.2% per sample, and second largest being 0.5 % per sample. These cyanobacteria were classifiable only to the level of order, but all belonged to Gastranaerophilales, an order that - rather surprisingly - consistently lacks both photosynthetic, and aerobic pathways [Rochelle M Soo et al, Science 2017, vol 355, issue 6332, pp. 1436-1440]. The lack of aerobic metabolism makes it probable that the finding is not incidental: these cyanobacteria may indeed be present in the gastrointestinal tract, as the order name suggests and as has been documented by Soo et al in an earlier submission to the Sequencing Reads Archives (https://www.ncbi.nlm.nih.gov/bioproject/PRJNA348149). However, we think it is prudent to delete this negligible portion of reads: (a) the power to detect an association with the outcome is close to zero due to the low abundance of the bacteria, (b) it would confound readers, as cyanobacterium is mostly thought of as a plant predecessor, an organism that can photosynthesize; thus it is often automatically removed like we did.

Comment:

Line 237 - There’s an extra comma between “or greater” and “a variance >10%”.

Response:

It has been addressed (now line 271).

Comment:

Line 340 - This is the second sentence in a row to start with “Also”. Consider using “Finally”, another transition word, or nothing at all.

Response:

The transition word was changed to “In addition” (now line 413).

Comment:

Line 345 - I would suggest you move the reference to Fig 3 to after “with each other” which is what is displayed in the figure - if you decide to keep it, see above.

Response:

We decided to remove the figure per your previous comment about it.

Comment:

Line 370 - Please specify that it is BMI z-score

Response:

We have now specified that it is BMI z-score (now line 443). Similar specifications were made throughout the manuscript.

Additional requirements:

Comment:

Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

Response:

We have followed the style requirements per the comment, and our revised manuscript reflects this.

Comment:

We note that you have stated that you will provide repository information for your data at acceptance. Should your manuscript be accepted for publication, we will hold it until you provide the relevant accession numbers or DOIs necessary to access your data. If you wish to make changes to your Data Availability statement, please describe these changes in your cover letter and we will update your Data Availability statement to reflect the information you provide.

Response:

The data will be provided via Mendeley Data as we had originally planned under the following DOI link: http://dx.doi.org/10.17632/cwj76cbvc9.1. The items to be included there are: 1) S1 Table 1 (as referenced in the manuscript) containing the individual participant’s gender, age, BMI, BMI z-score, as well as the kilocalorie and macronutrient daily percentage composition one and two days prior to sampling; 2) unrarefied source data for the 16S rRNA gene sequencing analysis; 3) Metabolite concentrations in mg/g derived from Chenomx NMR Suite version 7.5 for each of the 52 study participants; and 4) the 1H NMR spectra for the 52 study participants.

Comment:

In your Methods section, please provide additional information about the participant recruitment method and the demographic details of your participants. Please ensure you have provided sufficient details to replicate the analyses such as: a) the recruitment date range (month and year), b) a description of any inclusion/exclusion criteria that were applied to participant recruitment, c) a table of relevant demographic details, c) a description of how participants were recruited.

Response:

This information has now been more explicitly stated in the methods subsection “Study participants.”

Comment:

We suggest you thoroughly copyedit your manuscript for language usage, spelling, and grammar. If you do not know anyone who can help you do this, you may wish to consider employing a professional scientific editing service.

Response:

We have copyedited our manuscript. All revisions can be followed via Track Changes.

Comment:

Please provide a sample size and power calculation in the Methods, or discuss the reasons for not performing one before study initiation.

Response:

Given that this is an exploratory pilot study, we did not have a clear hypothesis about which metrics would be expected to be different among the study groups, thus an accurate power calculation did not seem suitable nor feasible. Also, the study was limited in time and funding, thus we were limited on the cohort size and recruitment time possibilities.

Attachment

Submitted filename: Response_to_Reviewers.doc

Decision Letter 1

Suzanne L Ishaq

31 Dec 2020

PONE-D-20-27287R1

Stool metabolome-microbiota evaluation among children and adolescents with obesity, overweight, and normal-weight using 1H NMR and 16S rRNA gene profiling

PLOS ONE

Dear Dr. Havlík, ČZU v Praze,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

The authors have done a great deal of work to revise their manuscript, and the reviewers and I were pleased to see that the changes improved the manuscript.  A few additional considerations have been mentioned which may require some consideration by the authors, and a handful of very minor corrections have been noted.

Please submit your revised manuscript by Feb 14 2021 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols

We look forward to receiving your revised manuscript.

Kind regards,

Suzanne L. Ishaq, PhD

Academic Editor

PLOS ONE

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #1: (No Response)

Reviewer #2: All comments have been addressed

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Partly

Reviewer #2: Yes

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: No

Reviewer #2: Yes

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: 1. I appreciate the author’s providing more information about diet. I still have some additional questions/concerns. Was this an outpatient or inpatient study? If inpatient I assume that diet was controlled by the staff (although explicit information would be helpful). However, if this was an outpatient study, how was dietary management implemented? Were meals provided by the study, or were meals prepared by subjects/subject’s families? Additionally, compliance with dietary guidance is a well-established issue in outpatient studies. Was this controlled at all? Finally, how long were subjects on the controlled diet prior to sampling? This would be important to determine whether the observed changes were a response to stimuli (diet) or a new steady-state composition/function of the microbiome and metabolites.

2. I appreciate the additional information regarding control subjects, thank you! It might be interesting to compare reference data sets (e.g., HMP, other pediatric studies) to determine whether the controls in this study are similar to others, but that does not need to be a requirement for publication.

3. I appreciate the additional information on participants, but the comment was in regard to the mock community used for sequencing controls.

5. I appreciate the expanded discussion, thank you! I would recommend revising the wording of the statement “Despite consuming less kcal, the OW and OB groups still produced significantly more butyrate, which has been identified as the main energy supplier for colonic epithelial cells [8].” The measurement in this case is of butyrate in feces – which is butyrate produced by the microbiota but not consumed by the colonic epithelium.

6. This new figure conveys much additional information but is only at the phyla level. It would be helpful to include a genus level figure in addition to (not in replace of) the phyla level results. Additionally, the unsupervised clustering really shows the lack of segregation of microbial communities by group. I would suggest adding to the discussion the notion that while there are minimal differences in microbial community composition between groups, the metabolite data suggests that there may be differences in the metabolic activity of these microbes.

7. Thank you for the response. I think that this is fine but should be mentioned in the manuscript. Perhaps a more appropriate way to address this is to state that, while the significance of the metabolites does not survive correction using FDR, there are trends of interest given the sample size in this study. I agree that this data is an important and useful addition to the field!

Reviewer #2: All of my previous concerns were addressed to my satisfaction and comments from the other reviewer and editor appear to be addressed as well. I appreciate the addition of the complete Spearman correlation analysis and feel that this helped round out the discussion of the increased energy harvest hypothesis.

I would suggest the following, very minor, changes before publication:

1. Lines 313 and 314, replace p<0.001 with exact p-values, if possible.

2. Line 398, consider replacing “authors” with “instigators”, only because I was immediately looking for authors of another study.

3. Line 422 unnecessarily uses “directly” twice; I would suggest removing the second usage.

4. For showing taxonomic abundance (Figure 3), I prefer stacked barcharts, but this is clearly a personal preference and given that the other reviewer specifically asked for a heatmap it works. Either is preferable to a pie chart.

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: Yes: Elliot S. Friedman

Reviewer #2: Yes: Laura Tipton

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

PLoS One. 2021 Mar 25;16(3):e0247378. doi: 10.1371/journal.pone.0247378.r004

Author response to Decision Letter 1


6 Jan 2021

Response to reviewers.

Reviewer 1:

Comment:

I appreciate the author’s providing more information about diet. I still have some additional questions/concerns. Was this an outpatient or inpatient study? If inpatient I assume that diet was controlled by the staff (although explicit information would be helpful). However, if this was an outpatient study, how was dietary management implemented? Were meals provided by the study, or were meals prepared by subjects/subject’s families? Additionally, compliance with dietary guidance is a well-established issue in outpatient studies. Was this controlled at all? Finally, how long were subjects on the controlled diet prior to sampling? This would be important to determine whether the observed changes were a response to stimuli (diet) or a new steady-state composition/function of the microbiome and metabolites.

Response:

We have elaborated on this information in the subsection Study Participants. It was an inpatient study (lines 111-112, 127), the diet was planned by a clinical dietitian, and the food prepared by the cafeteria kitchen of the Olivova Children’s Medical Institution and (lines 131-133). For further clarity, we added more details about the diet in lines 131-138 and added a statement regarding compliance (leftover food and/or additional intake of other items outside the provided meals could not be accounted for) in lines 139-140. The participants were not all sampled at the same time and sampling took place throughout the study period with the earliest collections taking place after at least one week of habituation to the prescribed diet (lines 142-144). Also, as noted in lines 137-138, the meals were based on recipes and foods typically eaten in a standard Czech school and home diet, thus, except for portion control, the meals did not represent an adjustment for most participants.

Comment:

I appreciate the additional information regarding control subjects, thank you! It might be interesting to compare reference data sets (e.g., HMP, other pediatric studies) to determine whether the controls in this study are similar to others, but that does not need to be a requirement for publication.

Response:

We did not add this to the manuscript, but we did take a look at some other control groups in studies that also divided youth into normal, overweight, and obese categories. The table appears in the "Response to Reviewers" letter that has been uploaded.

Comment:

I appreciate the additional information on participants, but the comment was in regard to the mock community used for sequencing controls.

Response:

We have now added the detailed composition of the mock community (lines 238-244).

Comment:

I appreciate the expanded discussion, thank you! I would recommend revising the wording of the statement “Despite consuming less kcal, the OW and OB groups still produced significantly more butyrate, which has been identified as the main energy supplier for colonic epithelial cells [8].” The measurement in this case is of butyrate in feces – which is butyrate produced by the microbiota but not consumed by the colonic epithelium.

Response:

We have revised the wording of this statement to be clear that there was a higher content of fecal butyrate, but not necessarily that more butyrate was produced (lines 398-401).

Comment:

This new figure conveys much additional information but is only at the phyla level. It would be helpful to include a genus level figure in addition to (not in replace of) the phyla level results. Additionally, the unsupervised clustering really shows the lack of segregation of microbial communities by group. I would suggest adding to the discussion the notion that while there are minimal differences in microbial community composition between groups, the metabolite data suggests that there may be differences in the metabolic activity of these microbes.

Response:

To depict data from another angle, we have now added a stacked bar charts figure at the genus level (Fig 4) showing the 20 most abundant taxa (by relative abundance), as well as the two genera which are significant (Escherichia and Tyzzerella subgroup 3). To keep the figure more readable and due to the very low relative abundances of most taxa, not all 83 identified genera were shown in the figure. We also added on the notion that gut microbiota functional activity, rather than composition, may have played a part in our observations (lines 479-487).

Comment:

Thank you for the response. I think that this is fine but should be mentioned in the manuscript. Perhaps a more appropriate way to address this is to state that, while the significance of the metabolites does not survive correction using FDR, there are trends of interest given the sample size in this study. I agree that this data is an important and useful addition to the field!

Response:

As suggested, we have now mentioned and addressed FDR in the manuscript (lines 220, 315-319).

Reviewer 2:

Comment:

Lines 313 and 314, replace p<0.001 with exact p-values, if possible.

Response:

We have not made this change due to the p-values being quite small (p = 2.220E-16 for acetate with butyrate, p = 3.363E-06 for arabinose with galactose), and to keep consistency with the number of decimal places for the other reported p values.

Comment:

Line 398, consider replacing “authors” with “instigators”, only because I was immediately looking for authors of another study.

Response:

Edited as suggested (line 415).

Comment:

Line 422 unnecessarily uses “directly” twice; I would suggest removing the second usage.

Response:

Edited as suggested (line 439).

Comment:

For showing taxonomic abundance (Figure 3), I prefer stacked barcharts, but this is clearly a personal preference and given that the other reviewer specifically asked for a heatmap it works. Either is preferable to a pie chart.

Response:

Bar charts are a very good way to represent this information, and we have now added a stacked bar chart (Fig 4) based on genera % relative abundance to provide another angle to look at the taxonomic data.

Attachment

Submitted filename: Response_to_Reviewers.doc

Decision Letter 2

Suzanne L Ishaq

8 Feb 2021

Stool metabolome-microbiota evaluation among children and adolescents with obesity, overweight, and normal-weight using 1H NMR and 16S rRNA gene profiling

PONE-D-20-27287R2

Dear Dr. Havlík, ČZU v Praze,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Suzanne L. Ishaq, PhD

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #1: All comments have been addressed

Reviewer #2: All comments have been addressed

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Yes

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: Yes

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: (No Response)

Reviewer #2: (No Response)

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: Yes: Elliot S. Friedman

Reviewer #2: Yes: Laura Tipton

Acceptance letter

Suzanne L Ishaq

12 Mar 2021

PONE-D-20-27287R2

Stool metabolome-microbiota evaluation among children and adolescents with obesity, overweight, and normal-weight using 1H NMR and 16S rRNA gene profiling

Dear Dr. Havlík:

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

If we can help with anything else, please email us at plosone@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Suzanne L. Ishaq

Academic Editor

PLOS ONE

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    S1 Table. Characteristics of the 52 participants.

    T1 and T2 refer to one and two days prior to the sampling date. The kcal amount is per the entire day.

    (XLSX)

    Attachment

    Submitted filename: Response_to_Reviewers.doc

    Attachment

    Submitted filename: Response_to_Reviewers.doc

    Data Availability Statement

    All data files are available from Mendeley Data under the following DOI link: http://dx.doi.org/10.17632/cwj76cbvc9.1. The items included there are: 1) S1 Table 1 (as referenced in the manuscript) containing the individual participant’s gender, age, BMI, BMI z-score, as well as the kilocalorie and macronutrient daily percentage composition one and two days prior to sampling; 2) unrarefied source data for the 16S rRNA gene sequencing analysis; 3) Metabolite concentrations in mg/g derived from Chenomx NMR Suite version 7.5 for each of the 52 study participants; and 4) the 1H NMR spectra for the 52 study participants.


    Articles from PLoS ONE are provided here courtesy of PLOS

    RESOURCES